Daktari Enters Collaboration Agreement with Merck

Daktari Diagnostics today announced a collaboration with Merck to develop Daktari’s rapid hepatitis C virus (HCV) screening test. The deal, worth up to $8.5 million over the next 3.5 years, will support an accelerated development timeline for the clinical validation and regulatory approval of Daktari’s HCV test.

http://daktaridx.com/ddx2015/wp-content/uploads/2015/08/Daktari_News_2015_31Aug_MerckHCVPartnership.pdf

---------------------------